Sinclair Pharma Ltd
http://www.sinclairpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Sinclair Pharma Ltd
Cancer, Gene Therapy Top US FDA’s Second Half 2024 User Fee Calendar
Novel agents in immuno-oncology headline the drug center’s upcoming goal dates, while gene therapies make up most of the biologic center’s workload.
Rare Diseases Rule, But Some Common Conditions Stand Out In Pending US Applications
Half of the FDA’s upcoming 2024 user fee goals target rare diseases, but highly prevalent conditions like uncomplicated urinary tract infections and atopic dermatitis are also up for agency action in the second half of the year.
Obesity Rules Large-Cap Stocks In First Half Of 2024
Lilly and Novo Nordisk were top performers among large-cap pharma stocks, while the stock prices of Bristol Myers and Gilead declined the most.
Finance Watch: US Market May Warm To Go-Public Options As Summer Progresses
Public Company Edition: The IPO market in the US cooled in Q2, but a warm-up may come in Q3 alongside new SPAC merger opportunities; Artiva may be the next biopharma firm to go public. Also, IDEAYA and Recursion grossed $302.4m and $200m, respectively, in follow-on offerings.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Huadong Medicine Ltd
- Biosurface Pharma AB
- Laboratoire ObvieLine
- AQTIS Medical BV
- IS Pharma plc
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice